| Display title | Chemistry:Bevenopran |
| Default sort key | Bevenopran |
| Page length (in bytes) | 3,621 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 539792 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Smart bot editor |
| Date of page creation | 07:39, 6 March 2023 |
| Latest editor | imported>Smart bot editor |
| Date of latest edit | 07:39, 6 March 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached... |
